VistaGen Therapeutics Inc. (NASDAQ:VTGN) currently has a daily average trading volume of 3.41M but it saw 800967 shares traded on Thursday. With a market cap of 29.99M USD, stock’s current market price of $0.13 came falling about -0.83 while comparing to the previous closing price of $0.13. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.22 and as low as $0.08. In the recent trading on the day, stock has struck highest price mark of $0.1373 while lowest mark touched by it was $0.13.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Taking a look at 20-day trading activity of VistaGen Therapeutics Inc. (VTGN) gives us an average price of $0.1364, while its current price level is -89.17% below from 52-week high level whereas it is 72.01% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.1372 while that of 200 days or SMA-200 reads an average of $0.1528. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.64% during that period while stretching the period over a month that increases to 7.53%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 43.97 which implies that the stock is in neutral territory.
VistaGen Therapeutics Inc. (VTGN)’s stock is currently under the radar of 1 analysts who are in consensus at a 12-month price target range of between $0.25 and $0.25 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $0.25 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $0.25. Average price target assigned by them is $0.25 which highlights an upside potential of 48.0% for the stock over that period. And to attain the median price target of $0.25 assigned by those analysts, stock has to add about 48.0% of value to its current levels.
Data by FactSet Research shows that 1 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 0 analysts suggested the investors to Buy the stock while 1 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Hold for the stock and that issued by Wall Street to investors is Hold.
Over the week, VTGN’s stock price is moving -6.77% down while it is -3.22% when we observe its performance for the past one month. Year-to-date it is 28.25% up and over the past year, the stock is showing a downside performance of -87.05%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2022, when its quarterly earnings per share (EPS) of -$0.05 beat the consensus estimate of -$0.07 for the same. The company is expected to be releasing its next quarterly report in 08/15/2023, for which analysts forecasted an EPS of -$0.05 while estimate for next year EPS is -$0.28. For VTGN, analysts are forecasting an EPS-growth rate of -12.00% for current year and estimate for EPS growth in next year is -7.10%.
Currently, VistaGen Therapeutics Inc.’s total number of outstanding shares is 206.84M with 0.84% of that held by the insiders while 19.50% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -73.90% and return on equity (ROE) at -158.20%. Stock’s beta reads 0.97. Stock has a price to book (P/B) ratio of 1.32. Its return on asset (ROA) is -125.10% on average.
A filing at the U.S. Securities and Exchange Commission revealed that iShares Russell 2000 ETF came shrinking its share ownership by -1.44% in the VistaGen Therapeutics Inc. (VTGN) decreasing its stake to 1.90% with control over 61120.0 shares in the company. In the most recent quarter, Fidelity Small Cap Index Fund came rising its stake by 11.73% in the company and now holds 1.62 million or 0.74% of the company’s stake having worth of about 0.23 million.
Leave a Reply